Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Drug Therapy × Breast × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 93 Triple Negative Breast Neoplasms 21 Neoplasm Metastasis 6 Lung Neoplasms 5 Pancreatic Neoplasms 4 Neoplasms 4 Colorectal Neoplasms 4 Colonic Neoplasms 4 Stomach Neoplasms 3 Ovarian Neoplasms 3 Melanoma 3 Esophageal Neoplasms 3 Sarcoma 2 Lymphoma 2 Liver Neoplasms 2 Head and Neck Neoplasms 2 Gastrointestinal Neoplasms 2 Fatigue 2 Cholangiocarcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Urogenital Neoplasms 1 Patient Acceptance of Health Care 1 Oropharyngeal Neoplasms 1 Neoplasms by Site 1 Multiple Myeloma 1 Mouth Neoplasms 1 Motor Activity 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Trastuzumab 3 pyrotinib 2 pertuzumab 2 Fulvestrant 2 tucatinib 1 palbociclib 1 disitamab vedotin 1 atezolizumab 1 RC48 antibody 1 Drug Therapy 1 Docetaxel 1 Capecitabine 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡